Arthros | Patient Deep Dive
SMOKING & ALCOHOL
• Angelo Papachristos PT, ACPAC • Unity Health Toronto
Smoking matters more for your arthritis than your evening glass of wine
The evidence on cigarettes in inflammatory arthritis is much stronger than the evidence on moderate drinking, and patients deserve to know which is which.
A man in his mid-thirties came in three months into methotrexate and adalimumab for rheumatoid arthritis. Mornings were a little better. Not great. He pulled out his phone and asked the two questions I hear together more than any others: was quitting smoking really going to do something for his joints, or was that just what doctors said? And the glass of red he had with dinner most nights, was that really a problem?
Smoking does more to your arthritis than the lifestyle pamphlet suggests
The standard message is that smoking is bad for you. True, but it understates the magnitude in inflammatory arthritis.
In rheumatoid arthritis, smoking is the strongest known environmental risk factor for getting the disease in the first place. The Swedish EIRA study, published by Klareskog and colleagues in Arthritis & Rheumatism in 2006, showed that people who smoked and carried a specific genetic variant (called the HLA-DRB1 shared epitope, a piece of immune-system code that many people with antibody-positive RA share) had dramatically higher risk of developing the antibody-positive form of the disease than people with either factor alone. Antibody-positive RA is the type that drives more joint erosion and more aggressive disease.
Once RA is established, smoking keeps shaping outcomes. Work by Saevarsdottir and colleagues using the BARFOT early-arthritis cohort and the Swedish Rheumatology Quality Register showed that current smokers are meaningfully less likely to respond well to methotrexate or to TNF inhibitors (biologics like adalimumab and etanercept). The gap is on the order of a 30 percent relative reduction in the chance of reaching low disease activity in the first year of treatment. That is a sizable difference, comparable in magnitude to the difference between an effective and a less effective drug choice.
Axial spondyloarthritis tracks similarly. The French DESIR cohort and other European registries have linked smoking to higher disease activity and faster radiographic progression of the spine. Function declines more quickly over follow-up. Smokers with axSpA tend to start biologic therapy earlier and switch agents more often, which suggests the disease is harder to control.
For lupus, smoking is associated with more skin involvement and reduced hydroxychloroquine response, though the population-level effects are smaller than in seropositive RA. For osteoarthritis, the connection between smoking and the disease itself is modest. The cleaner finding involves surgery: smokers heal more slowly after joint replacement and have higher rates of wound infection and prosthetic joint infection. If knee or hip replacement is on your horizon, quitting six to eight weeks beforehand measurably changes those rates.
Most of this evidence is observational. Smokers and non-smokers differ in many ways that statistical adjustment cannot fully untangle. Randomized trials of smoking cessation in established arthritis exist but are small. The signal is consistent enough across large registries and across multiple rheumatic diseases that I trust the broader picture, which is why smoking comes up at the first visit and not after a year of disappointing treatment response.
The alcohol conversation patients deserve
The default clinic advice is often 'no alcohol on methotrexate.' That is stricter than the evidence supports for most patients.
Methotrexate is processed by the liver, alcohol stresses the liver, and the combined burden was assumed to push liver enzyme elevations toward scarring over time. Older studies in patients on higher methotrexate doses with less regular blood monitoring did show liver problems with concurrent drinking. The picture today is more specific.
A UK cohort study from the BSRBR-RA registry (a national database of RA patients on biologics), published by Humphreys and colleagues in Annals of the Rheumatic Diseases in 2017, looked at thousands of patients on methotrexate and tracked their alcohol intake against liver enzyme abnormalities. Drinking within UK national alcohol guidelines, which work out to roughly a small glass of wine most nights, was not associated with a clinically meaningful increase in abnormal liver tests. Higher intake was. The British Society for Rheumatology now permits moderate alcohol consumption on methotrexate for patients with stable liver enzymes and no other liver disease risk, provided monitoring is reliable.
The Canadian Rheumatology Association tends to be more conservative, partly because metabolic liver disease in Canada is rising and the underlying population context differs. Your rheumatology team's advice should be taken seriously because they know your liver tests, your weight, your other medications, your hepatitis history, and the rest of your specific risk profile.
Other rheumatology medications interact with alcohol differently. NSAIDs combined with alcohol meaningfully increase the risk of stomach ulcers and gastrointestinal bleeding, in a dose-dependent way that worsens with each additional drink. Prednisone amplifies the bone-loss and blood-sugar effects of alcohol, which is relevant for anyone on long-term steroids. Allopurinol works against alcohol's tendency to trigger gout attacks, so heavy drinking can negate the medication. Hydroxychloroquine and sulfasalazine don't have direct alcohol interactions of clinical importance. Most biologics (adalimumab, etanercept, rituximab) don't either, though excessive drinking carries its own infection and liver risks independent of the drug list.
What actually changes when you quit smoking
In RA, treatment response improves within months of quitting. Cohort data from Sweden and elsewhere show that patients who quit smoking after diagnosis are more likely to reach low disease activity on methotrexate than those who continue. C-reactive protein, a measure of inflammation, comes down. The rate of joint damage on radiographs slows.
In axSpA, quitting is associated with slower spinal damage over years. The biggest gains accrue to people who quit early, before structural change has set in, but quitting later still helps the symptoms (pain and stiffness) that patients feel day to day.
Cardiovascular benefits show up faster than musculoskeletal ones. Within a year of quitting, your risk of heart attack drops substantially. This matters because RA itself raises cardiovascular risk independent of smoking, and the two factors compound. Bone density stabilizes over a few years. Cancer risk falls over a decade or more.
The man with rheumatoid arthritis wanted a number. He wanted to know that quitting would shrink his morning stiffness by some specific minutes, or that his methotrexate would work that much better. I couldn't promise him those specifics because cohort data describe averages across populations, not individuals. What I could tell him: among patients like him, three months into combination DMARDs with partial response, the ones who quit smoking do better over the next year than the ones who don't. Whether his particular morning stiffness would shrink by twenty minutes or two hours, neither of us could know in advance. The direction was the thing he had control over.
Cutting down is not equivalent to quitting. Patients negotiate. They drop from a pack a day to half a pack. They switch to vaping. The evidence does not support those compromises as adequate for inflammatory arthritis. Light smoking still drives the citrullination biology that produces anti-CCP antibodies in RA. We don't yet have good long-term data on vaping in inflammatory arthritis populations, and there is no biological reason to assume vaping is safe for joints.
What to do, and the conversation to have
If you smoke and have rheumatoid arthritis, axial spondyloarthritis, or psoriatic arthritis, the highest-impact behavioural change you can make for your treatment response is stopping smoking completely. Ask your rheumatology team for a cessation referral. Nicotine replacement and prescription cessation medications (bupropion, or varenicline where it is available) roughly double the odds of quitting compared with willpower alone, and your team can arrange the prescription. If you drink alcohol and take methotrexate, ask your rheumatologist what your specific situation allows. Bring honest numbers (your actual drinks per week, not a softened version) and your last set of liver tests. For many patients with stable enzymes and no other liver risk factors, a small amount of alcohol most days is compatible with safe methotrexate use. The conversation works better when you tell your team what you are actually doing.
What this does not mean
None of this is permission to keep smoking because biologics will pick up the slack, and it is not licence to drink heavily on methotrexate because some patients tolerate moderate intake. If your rheumatologist has told you something more restrictive, that advice probably reflects something specific about your situation that this article cannot know.
References
EIRA: smoking and the HLA-DRB1 shared epitope in seropositive RA. Klareskog L et al. A new model for the etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis & Rheumatism, 2006.
https://onlinelibrary.wiley.com/doi/10.1002/art.21575
Smoking and treatment response on methotrexate and TNF inhibitors. Saevarsdottir S et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the EIRA study and the Swedish Rheumatology Register. Arthritis & Rheumatism, 2011. https://onlinelibrary.wiley.com/doi/10.1002/art.27758
Alcohol intake and liver enzyme elevation on methotrexate. Humphreys JH et al. Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate. Annals of the Rheumatic Diseases, 2017.
DESIR cohort: smoking and outcomes in early axial spondyloarthritis. Chung HY, Machado P, van der Heijde D, et al. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life. Annals of the Rheumatic Diseases, 2012.
This article is for patient education and does not constitute medical advice. Treatment decisions, medication changes, and behavioural commitments should be made together with your rheumatology team, who knows your full history, comorbidities, current medications, and the local context your care sits within.
Angelo Papachristos PT, ACPAC • Advanced Practice Physiotherapist • Martin Family Arthritis Care & Research Centre, St. Michael’s Hospital, Unity Health Toronto
Co-Founder, RheumAcademy - Arthros
Canada’s Rheumatology Education Platform
Connecting the System Around the Patient Built by Clinicians • Backed by Evidence • Designed for Scale